3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Sarcopenia
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Peripheral Nervous System Diseases
1
Myelodysplastic Syndromes
1
Leukemia, Myeloid
1
Heart Failure
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Cardiotoxicity
1
Breast Neoplasms
1
Anemia, Aplastic
1
Interventions
Control Groups
2
Atorvastatin
2
sacubitril and valsartan sodium hydrate drug combination
1
pertuzumab
1
nicotinamide-beta-riboside
1
empagliflozin
1
dapagliflozin
1
candesartan
1
Trastuzumab
1
Sodium Chloride
1
Simendan
1
Pyruvic Acid
1
Population Groups
1
Ogivri
1
Metoprolol
1
Hydroxymethylglutaryl-CoA Reductase Inhibitors
1
Eplerenone
1
Carvedilol
1
Ado-Trastuzumab Emtansine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Heart Failure
×
nicotinamide-beta-riboside
×
Clear all
NCT05732051
2023-03-17
NARNIA
University Hospital, Akershus
Phase 2
Recruiting
60 enrolled